Report: How Abortion Drug Sellers Are Violating Federal Rules Designed to Protect Women
Author: Kate Quiñones/EWTN News English | National Catholic Register
Original date: May 29, 2026
Article highlights
Most abortion drug sellers are flouting a federal rule that protects women from complications from chemical abortions, according to a recent report.
The May 26 report by Charlotte Lozier Institute, a think tank affiliated with Susan B Anthony Pro-Life America, examined the telehealth abortion landscape and investigated whether abortion drug providers follow U.S. Food and Drug Administration (FDA) requirements.
Titled “An Overview of Online Abortion Drug Access in Post-Dobbs America,” it found numerous alleged violations…
Mia Steupert, research associate at the institute and the reportʼs author, called the findings “egregious.”
“The abortion industry loves to claim ‘abortion is healthcare,’ but their actions and advocacy have shown they don’t want abortion to be treated with the same level of regulatory scrutiny as legitimate medical procedures,” Steupert said. …
Andrea Trudden, a spokeswoman for Heartbeat International, … said the report “confirms exactly what many of us warned would happen when abortion pills were deregulated.” …
“Ironically, the more the abortion industry markets abortion as ‘reproductive healthcare,’ the fewer actual healthcare professionals tend to be involved in the process,” Trudden continued. “Women are increasingly being pushed toward mail-order abortion drugs with little medical oversight, no in-person examination, no ultrasound, and in some cases apparent disregard even for FDA safety limits.”